29 July 2020
Visiongain has launched a new report Pharmacokinetics Services Market Report 2020-2030: Forecasts by Drug Type (Small Molecules, Large Molecules) and by Region (North America, Europe, Asia Pacific, Latin America & MEA), Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.
Pharmacokinetics is a branch of pharmacology that helps to study how the body affects any specific drug after administration. It helps to analyse the metabolic changes that the drug will undergo from the time of administration to complete elimination. This study helps researchers understand the chemical changes that a drug will undergo and how it is affected by the dosage of drug and the route of administration. Pharmacokinetics helps to understand the rate of drug attrition. Pharmaceutical companies are adopting the trend of pharmacokinetic analysis to reduce the risk of high drug attrition. Thus, the increase in attrition rate of drugs undergoing clinical trials owing to poor pharmacokinetics is a major factor increasing the demand for pharmacokinetics services.
As there is risk of drug attrition in advanced clinical trial phases, pharmacokinetic investigations should be conducted at each developmental stage. These investigates help to determine modifications that would be required to avoid any potential challenges that may be caused during later stage of drug development. Furthermore, pharmacokinetic studies also help in other drug discovery functions such as clinical pharmacology and toxicology. Thus, pharmacokinetic has gained importance in drug discovery and development and regulatory bodies have increased focus to standardize pharmacokinetic protocols.
The increase in the number of pipeline products and ongoing clinical trials and conference focused on increasing awareness regarding the importance of pharmacokinetics further drives the growth of global pharmacokinetics services market. As each drug candidate requires different pharmacokinetic protocol, it is a time consuming and expensive process. Thus, the high cost of pharmacokinetics studies is expected to hamper the market growth. Limitations relate to in vitro pharmacokinetic studies such as lack of standardized protocol to predict complete interactions of target organ and drug candidate is also expected to thwart the market growth.
The Visiongain report analyst commented “the rise in awareness regarding the importance of implementing pharmacokinetic studies during drug discovery and development have motivated the regulatory bodies to standardize pharmacokinetic protocols, which in turn will increase the demand for pharmacokinetic services. The increase in the number of drugs in pipeline and the need to reduce high drug attrition during each phase of clinical trial are further driving the growth of the pharmacokinetics services market”.
The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include Evotec AG,Certara, L.P., Pacific BioLabs, GVK Biosciences Private Limited, Shanghai Medicilon Inc., Pharmaceutical Product Development, LLC, Charles River Laboratories International, Inc., PAREXEL International Corporation, Eurofins Scientific, Inc., and Frontage Labs.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.
03 December 2020
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.
03 December 2020
Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.
03 December 2020
All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.